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Abstract
Background Generalized convulsive status epilepticus
(GCSE) is a medical emergency associated with high
morbidity and mortality that requires prompt medical
intervention. Topiramate (TPM) is an antiepileptic drug
effective against a broad spectrum of seizure types, and has
been proposed as a possible therapeutic option for super-
refractory status epilepticus (SRSE), the most severe form
of GCSE.
Aim This review aimed to evaluate the role of TPM in
GCSE, including SRSE.
Methods MEDLINE, CENTRAL, ClinicalTrials.gov,
LILACS, Google Scholar, and Opengrey.eu were system-
atically searched. We compared: (1) patients who did and
who did not receive TPM as their last drug; (2) patients
receiving TPM as the last drug and achieving SE control
and patients receiving TPM as the last drug but without
termination of SE.
Results The literature search yielded 1164 results, with
individual data available for 35 patients (six with SRSE)
from four studies. SE was controlled in 68.6% of patients
receiving TPM either as the last drug (20) or not (15), and
in 14 of the 20 patients receiving TPM as the last drug
(70%). Only six patients received TPM for SRSE; in five of
them, TPM was administered as the last drug with reso-
lution of SE in four. When comparing patients who did and
did not receive TPM as the last drug, no statistically sig-
nificant difference was found for any of the variables
considered; similarly, no difference was found comparing
patients receiving TPM as the last drug and achieving SE
control with those receiving TPM as the last drug but
without termination of SE.
Conclusions The lack of a statistically significant difference
is likely to be due to the small sample size. In only a few
patients was TPM used for SRSE. There is an unmet need for
high-quality studies to evaluate the role of TPM in GCSE.
Electronic supplementary material The online version of this
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In this individual patient data analysis, the first to be
conducted in status epilepticus (SE), we did not find
any variable associated with a likely response to
topiramate (TPM). However, considering the
relatively small number of patients analyzed, the
lack of a statistically significant difference may be
due to statistical error type II.
The number of patients with super-refractory status
epilepticus (SRSE) treated to date with TPM is
probably much lower than commonly reported and is
definitely too small to draw any conclusion about its
definite role in the treatment of this condition.
There is still an unmet need for high-quality
observational and interventional studies to evaluate
the role of TPM in SE, including SRSE.
1 Introduction
Status epilepticus (SE) is defined as ‘‘a condition resulting
either from the failure of the mechanisms responsible for
seizure termination or from the initiation of mechanisms,
which lead to abnormally prolonged seizures’’ [1]. This
condition represents a neurological and medical emergency
with an estimated crude incidence of 10–41/100,000
patients per year, an age-standardized incidence ranging
from 4.61/100,000 [2] to 18.3/100,000 [3], and an overall
mortality of 20% [4–6]. SE carries a high risk of long-term
consequences including death and, as such, it needs to be
promptly recognized and adequately treated.
Generalized convulsive (tonic–clonic) SE (GCSE) is
currently defined as a generalized tonic–clonic seizure
lasting more than 5 min [1]. The treatment of GCSE usu-
ally follows a stepwise approach, with initial administra-
tion of benzodiazepines followed by intravenous
antiepileptic drugs (AEDs) if seizure activity continues
[5, 6]. After failure of first- and second-line treatments, a
more aggressive approach consisting of anesthetics
(propofol, pentobarbital, thiopentone, midazolam, or keta-
mine) is required [5, 6]. However, SE may continue or
recur 24 h or more after the onset of anesthetic therapy, or
may recur on reduction or withdrawal of anesthesia; this
condition, which is associated with a mortality of 35% [7],
has been termed ‘‘super-refractory status epilepticus’’
(SRSE) [8]. The prognosis of SE strongly depends on its
duration, etiology, and intrinsic severity [9, 10]. However,
data on these prognostic factors are usually lacking in trials
assessing the efficacy of treatments for SE [11, 12].
Topiramate (TPM) is an AED that is effective against a
broad spectrum of seizure types, possibly reflecting its
multiple mechanisms of action. Topiramate has good oral
bioavailability, linear kinetics, low protein binding, and no
active metabolites [13]. In critically ill patients, TPM can
be titrated relatively quickly and has been listed among
possible therapeutic options for SRSE [7].
The aim of this systematic review with individual
patient data analysis was to evaluate the role of topiramate
(TPM) in GCSE, including SRSE.
2 Methods
A comprehensive review of the available literature was
performed to minimize publication bias. We systematically
searched MEDLINE, CENTRAL, LILACS, ClinicalTri-
als.gov, Google Scholar, and Opengrey.eu to identify
studies assessing the role of TPM in the treatment of adult
cases of GCSE and reporting individual patient data.
Search strategies are reported in the Supplementary
Material. Cases of post-anoxic SE and other subtypes of SE
were excluded. Similarly, studies conducted in pediatric
populations (\16 years of age) were excluded. To mini-
mize the risk of selective outcome reporting we also
excluded single case reports. There were no language
restrictions. All searches were conducted on 10 October
2016.
Retrieved articles were independently evaluated for
inclusion by two review authors; any disagreement was
resolved through discussion.
The following individual patient data were collected:
age, gender, weight, previous history of seizures, etiology
(acute symptomatic, remote symptomatic, progressive
symptomatic, epilepsy, unknown/not specified), EEG fea-
tures, degree of impairment of consciousness, status
epilepticus severity score (STESS) or Epidemiology-based
Mortality score in SE (EMSE), number of AEDs at
admission, number of AEDs prior to TPM administration,
route of TPM administration, loading dose of TPM,
maintenance dose of TPM, maximum daily dose of TPM,
time from SE to TPM administration, time from TPM
administration to response, control of SE (yes/no), need for
intubation (yes/no), death (yes/no), TPM used as last AED
(yes/no), name and order of AEDs used to treat SE.
Data were summarized using percentages, median,
range, or mean and standard deviation, whichever was
appropriate. Because TPM was not the last AED admin-
istered to all patients prior to termination of SE, we com-
pared patients who received TPM as the last drug and those
who did not. This comparison was performed to analyze
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whether there was any difference between the two groups
that might help to identify some variables predicting a
likely response to TPM. We also compared patients
receiving TPM as the last drug and achieving SE control to
patients receiving TPM as the last drug but without ter-
mination of SE.
Comparisons were conducted by analyzing variables
such as: age, gender, previous history of seizures, etiology,
number of AEDs prior to TPM, maximum daily dose of
TPM, patients with SE controlled, number of deaths, and
patients with TPM used as the last AED. Differences
between groups were calculated using the Mann–Whitney
U test, Chi-squared test, and Fisher’s exact test. A p value
of\0.05 was considered statistically significant. A Bon-
ferroni correction was applied to correct for multiple
testing.
3 Results
The literature search yielded 1164 articles (MEDLINE:
119; ClinicalTrials.gov: 1; CENTRAL: 4; Opengrey.eu: 0;
LILACS: 0; Google Scholar: 1040). After reading the full
text, 15 articles initially considered for possible inclusion
were eventually excluded (Fig. 1). Excluded articles with
reasons for exclusion and number of patients receiving
TPM for each excluded study are reported in the Supple-
mentary Material. Individual patient data were available
for 35 patients with GCSE (six of whom with SRSE) from
four studies [14–17]. The studies from which individual
patient data were extracted adopted retrospective
[14, 15, 17] and prospective [16] designs.
Individual patient data extracted are reported in the
Supplementary Material. Details on clinical features,
treatment, and outcomes of patients and results of statisti-
cal analyses are reported in Tables 1, 2 and 3.
Despite our primary intention, it was impossible to
analyze all variables initially considered because of lack of
information for some of them. Hence, only the following
data were analyzed: age, gender, previous history of sei-
zures, etiology (acute symptomatic, remote symptomatic,
progressive, epilepsy, unknown/not specified), number of
AEDs prior to TPM administration, maximum daily dosage
of TPM, control of SE (yes/no), death (yes/no), TPM used
as last AED (yes/no), order of AEDs used to treat SE.
Thirty-five patients with GCSE (median age: 40 years;
range: 16–92; 46% women) were included. In most cases
(69%), the etiology underlying GCSE was acute symp-
tomatic. In the majority of cases (69%), TPM was used as
third-line AED to control SE. Among the 35 patients
receiving TPM either as the last drugs (n = 20) or not
(n = 15), SE was controlled in 69%. In six out of 35
patients (17%), TPM was used to control SE, which
persisted after first-line and second-line treatments (ben-
zodiazepine followed by AED) and despite the use of
anesthetics (SRSE); in five out of these six cases, TPM was
administered as the last drug, with a resolution of SE in
four cases.
TPM was administered as the last drug in 57% of
patients (20/35), leading to SE control in 14/20 (70%)
cases.
No statistically significant difference was found for any
of the variables considered when we compared patients
who received TPM as the last drug to those who did not.
The only difference was in the proportion of women, which
was higher in those receiving TPM as the last drug (65 vs.
20%; p = 0.016); however, the statistical significance was
lost after applying the Bonferroni correction for multiple
comparisons (p[ 0.05). Similarly, no difference was
Fig. 1 Study flow diagram
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found comparing patients receiving TPM as the last drug
and achieving SE control with those receiving TPM as the
last drug but without termination of SE.
4 Discussion
This is the first attempt in the literature to perform an
individual patient data analysis in SE. Rather than
extracting aggregate data from published studies, individ-
ual patient data analyses are carried out using the original
research data reported in primary studies or provided by the
researchers responsible for each study. Individual patient
data can then be re-analyzed and combined, if appropriate,
into meta-analyses. Individual patient data analyses have
the potential to answer questions not posed by individual
studies or conventional meta-analyses, as they can improve
data quality and the type of analyses, producing more
reliable results [18]. As such, individual patient data
analyses are considered the gold standard of review.
However, as for conventional meta-analyses, their validity
depends on the quality of the individual patient data
obtained from primary studies.
The use of individual patient data analyses has been
particularly advocated for the assessment of the efficacy of
treatments for SE, a condition where several confounding
factors are usually not adequately reported and analyzed
with potential effect on the overall results [11, 19]. In this
scenario, individual patient data analyses may enable the
conduction of subgroup analyses not conducted by the
original researchers, taking into account relevant prog-
nostic aspects such as etiology and seizure type [19].
However, in order for these individual patient data analyses
to be reliable, it is necessary that the data being analyzed
are unbiased and complete for the variable(s) of interest.
Results of case reports including data on TPM in SE are
likely to be affected by selective outcome reporting bias
and positive-results publication bias, as favorable results
have a higher chance of being reported and published. For
this reason, data from case reports were not included in the
present review and analyses. Individual patient data were
extracted either from retrospective [14, 15, 17] or
prospective [16] trials. In all these studies the potential risk
for selective outcome reporting seems low, at least
according to the details provided in the methods section of
the published reports. Whether results obtained from these
studies actually provide a reliable picture, however,
remains unclear, as it is impossible to verify and quantify
the existence and the amount of unpublished studies where
TPM proved of limited utility in the treatment of SE.
However, despite searching multiple databases to identify
bibliographical references for gray literature, we were not
able to retrieve additional studies.
Hence, it is difficult to understand whether individual
patient data included and analyzed in the present review
reflect the prognosis of an unbiased patient population trea-
ted with TPM for SE. In other terms, it is unclear whether the
individual patient data collected and analyzed in our review
are truly representative of patients treated with TPM for SE
in terms of clinical and prognostic features.
However, even if the results had been obtained from
unbiased sources, it would have been impossible to analyze
the role of some prognostic factors such as duration of SE
and its intrinsic severity (e.g., assessed with STESS, or
EMSE), because of a lack of information on these
variables.
Table 1 Clinical features, treatment details, and outcomes of patients
receiving topiramate for generalized convulsive status epilepticus
Patients with
GCSE
No. of patients 35
Age, years Median: 40
(range 16–92)
Female, no. (%) 16 (45.7)




Acute symptomatic 24 (68.6)
Epilepsy 4 (11.4)
Remote symptomatic 4 (11.4)
Unknown 3 (8.6)
AEDs prior to TPM, no. Median: 2
(range 1–5)






TPM maximum daily dosage, mga Median: 400
(range 200–1000)
SE controlled, no. (%) 24 (68.6)
SE not controlled, no. (%) 11 (31.4)
Death, no. (%) 14 (40)
Super-refractory SE, no. (%)b 6 (17.1)
AEDs antiepileptic drugs, GCSE generalized convulsive status
epilepticus, SE status epilepticus, TPM topiramate
a Patients from the study by Hottinger et al. were excluded (no data
on maximum daily dosage was provided); data reported in the
table have been calculated from 32 patients
b We defined super-refractory status epilepticus as those cases where
seizure activity (assessed clinically and/or on EEG monitoring) per-
sisted after first-line and second-line treatments (benzodiazepine
followed by intravenous antiepileptic drugs) and despite use of
anesthetics (propofol, pentobarbital, thiopentone, midazolam, or
ketamine)
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Among the 35 patients receiving TPM either as the last
drug or not, SE was controlled in 69%. Conversely, SE was
terminated in 14 of 20 patients receiving TPM as the last
drug (70%). We considered these patients receiving TPM
as the last drug and achieving SE control as subjects in
whom TPM was possibly/probably successful. However, it
was impossible to adequately evaluate the definite efficacy
of TPM because not all studies provided information on the
time delay between TPM administration and SE resolution.
Furthermore, not all studies specified whether modification
of concomitant treatments were made in these patients.
No statistically significant difference was found when
comparing patients who received TPMas the last drug for any
of the variables considered and those who did not. Similarly,
no differencewas found comparing patients receivingTPMas
the last drug and achieving SE control with those receiving
TPMas the last drugbutwithout terminationofSE.Thehigher
proportion of women found to have received TPM as the last
drug was a false-positive result due to multiple comparisons,
as the statistical significance was lost after applying the
Bonferroni correction. Hence, we were unable to detect any
variable associated with a likely response to TPM. However,
considering the relatively small number of patients analyzed,
the lack of a statistically significant difference may be likely
due to statistical error type II.
Interestingly, in most cases TPM was used as second-
(11%) or third-line (69%) AED to control SE. This finding is
unexpected, as TPM is not recommended by any guidelines as
treatment for SE persisting despite failure of first- and second-
line treatments [20–24]. The use of TPM has been suggested
as an option for SRSE, i.e., SE continuing or recurring 24 h or
more after the onset of anesthetic therapy, or recurring on the
reduction or withdrawal of anesthesia [7]. However, in the
present review, only six patients (17%) received TPM for
SRSE; in five of these cases, TPMwas administered as the last
drug with resolution of SE in four cases.
In the literature, after excluding case reports, there is only
one study (not included in the present review as it did not
provide individual patient data) specifically assessing the
role of TPM in SRSE in adults [25], whereas one study has
evaluated TPM in SE continuing despite two adequately
dosed AEDs (i.e. ‘‘refractory SE’’) [26]. In the SRSE study,
among the 28 patients receiving TPM as the last drug and
discontinuing intravenous anesthetics with no additional
AEDs administered, cumulative cessation of RSE in patients
was 4/35 (11%) at 1 day, 10/35 (29%) at 2 days, and 14/35
(40%) at 3 days [25]. This retrospective study represents the
largest reported group of patients with SRSE treated with
TPM and suggests that TPMmight be useful in the treatment
of this serious condition in adult patients.
Table 2 Clinical features, treatment details, and outcomes of patients receiving topiramate as the last drug for treatment of generalized
convulsive status epilepticus
Patients with controlled GCSE
(TPM administered as last drug)
Patients with uncontrolled GCSE
(TPM administered as last drug)
Statistical difference
No. of patients 14 6
Age, years Median: 47.5 (range 16–92) Median: 41.5 (range 20–76) p = 0.562
Female, no. (%) 10 (71.4) 3 (50) p = 0.613
Patients with previous history of seizures, no. (%) 2 (14.3) 2 (33.3) p = 0.657
Etiology, no. (%) p = 0.666
Acute symptomatic 12 (85.7) 5 (83.3)
Epilepsy 1 (7.1) 0
Remote symptomatic 1 (7.1) 1 (16.7)
AEDs prior to TPM, no. Median: 2 (range 1–5) Median: 2.5 (range 1–5) p = 0.169
AEDs prior to TPM, no. (%)
1 3 (21.4) 1 (16.7)
2 8 (57.1) 2 (33.3)
3 0 2 (33.3)
4 2 (14.3) 0
5 1 (7.1) 1 (16.7)
TPM maximum daily dosage, mga Median: 400 (range 300–1000) Median: 550 (range 400–800) p = 0.280
Death, no. (%) 7 (50) 2 (33.3) p = 0.380
AEDs antiepileptic drugs, GCSE generalized convulsive status epilepticus, TPM topiramate
a Patients from the study by Hottinger et al. were excluded (no data on maximum daily dosage was provided); data reported in the table were
calculated from 18 patients (12 with controlled and six with uncontrolled GCSE)
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In their review, Ferlisi and Shorvon reported that the
published outcome of TPM in SRSE is ‘‘restricted to 60 cases
(in 10 reports) treated with topiramate’’ [8]. However, a
careful analysis of the data available in the literature indi-
cates that the number of patients with SRSE treated to date
with TPM is probably much lower than the reported figure,
even after including pediatric patients [27]. This is due to the
fact that studies conducted in ‘‘refractory SE’’ have high
clinical heterogeneity, as they include both patients with
SRSE and patients with SE refractory to first- and second-
line treatments but not receiving anesthetics [15–17, 26, 28].
Hence, the number of patients treated with TPM for SRSE is
certainly too small to draw any conclusion about its definite
role in the treatment of this condition.
The lack of information on TPM in SE can also be
attributed to the fact that, even when TPM is widely used,
single outcomes are usually not reported. For instance, in a
recent retrospective study, TPM was found to be used in 47
out of 341 patients (14%) [29], whereas in a 6-year cohort
study TPM was administered as a third-line drug in 34 out
of 171 patients (20%) [30]. These are just two examples of
the wide use of TPM in clinical practice. However, the fact
that none of them reported details on outcomes in subjects
receiving TPM further highlights the need for studies
reporting individual patient data.
5 Conclusions
No statistically significant difference was found for any of
the variables considered when we compared patients who
received TPM as the last drug to those who did not. Sim-
ilarly, no difference was found comparing patients
receiving TPM as the last drug and achieving SE control
with those receiving TPM as the last drug but without
termination of SE. As the present review demonstrates,
despite their potential to answer questions not posed by
individual studies or conventional meta-analyses, individ-
ual patient data analyses can do little if information has
been obtained by biased studies or if data are incomplete.
There is still an unmet need for high-quality observational
and interventional studies to evaluate the role of TPM in
SE, including SRSE. Several areas require attention in
future research in the treatment of SE: investigators should
use uniform definitions of SE and report results using clear
and uniform methods to facilitate meta-analysis [11, 12].
Table 3 Clinical features, treatment details, and outcomes of patients who did and did not receive topiramate as the last drug for treatment of
generalized convulsive status epilepticus
Patients with TPM used
as last drug
Patients with other AEDs
used as last drug
Statistical
difference
No. of patients 20 15
Age, years Median: 47.5 (range: 16–92) Median: 25 (range: 18–73) p = 0.929
Female, no. (%) 13 (65%) 3 (20) p = 0.016b
Patients with previous history of seizures, no. (%) 4 (20%) 3 (20) p = 1
Etiology, no. (%) p = 0.549
Acute symptomatic 17 (85%) 7 (46.7)
Epilepsy 1 (5%) 3 (20)
Remote symptomatic 2 (10%) 2 (13.3)
Unknown 0 3 (20)
AEDs prior to TPM, no. Median: 5 (range 3–5) Median: 2 (range 2–5) p = 0.076
AEDs prior to TPM, no. (%)
1 4 (20%) 0
2 10 (50%) 14 (93.3)
3 2 (10%) 0
4 2 (10%) 0
5 2 (10%) 1
TPM maximum daily dosage, mga Median: 425 (range 400–1000) Median: 400 (range 400–400) p = 0.066
Death, no. (%) 9 (45%) 5 (33.3) p = 0.728
SE controlled, no. (%) 14 (70%) 10 (66.7) p = 1
AEDs antiepileptic drugs, SE status epilepticus, TPM topiramate
a Patients from the study by Hottinger et al. were excluded (no data on maximum daily dosage was provided); data reported in the table were
calculated from 33 patients (four with SR-GCSE and 29 without SR-GCSE)
b The statistical significance was lost after applying the Bonferroni correction for multiple comparisons (p[ 0.05)
72 F. Brigo et al.
Providing individual patient data is crucial, as they may be
used to perform more detailed and informative analyses to
assess the role of confounders.
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